THERAPEUTIC SYNERGISM (TS) OF HOMOHARRINGTONINE (H) PLUS 5-FLUOROURACIL (FU) AGAINST LEUKEMIA P388 (P388/0) AND ARA-C-RESISTANT P388 (P388/ARA-C)

被引：0
|
作者：
LASTER, WR [1 ]
TRADER, MW [1 ]
SCHABEL, FM [1 ]
CORBETT, TH [1 ]
GRISWOLD, DP [1 ]
机构：
[1] SO RES INST,BIRMINGHAM,AL 35225
来源：
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH | 1982年 / 23卷 / MAR期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：199 / 199
页数：1
相关论文
共 50 条
  • [1] LEUKEMIA P388-TUMORS RESISTANT TO VINCRISTINE (P388/VCR), ADRIAMYCIN (P388/ADR), OR ARABINOSYLCYTOSINE (P388/ARA-C) - CROSS-RESISTANCE (P388/VCR AND P388/ADR) AND COLLATERAL SENSITIVITY (P388/ARA-C) TO HOMOHARRINGTONINE (H) (NSC 141633)
    WILKOFF, LJ
    DULMADGE, EA
    TRADER, MW
    SCHABEL, FM
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1982, 23 (MAR): : 199 - 199
  • [2] THERAPEUTIC SYNERGISM (TS) WITH L-ALANOSINE (A) PLUS N-PHOSPHONACETYL-L-ASPARTATE (PALA) AGAINST ARA-C-RESISTANT LEUKEMIA P388 (P388/ARA-C)
    TRADER, MW
    SCHABEL, FM
    LASTER, WR
    BROCKMAN, RW
    KOVACH, JS
    LIEBER, MM
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1982, 23 (MAR): : 187 - 187
  • [3] COMBINATION CHEMOTHERAPY OF P388/0 AND P388/ARA-C LEUKEMIAS WITH TIAZOFURIN AND SELECTED ANTITUMOR DRUGS
    HARRISON, SD
    TRADER, MW
    LASTER, WR
    GRISWOLD, DP
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1985, 26 (MAR): : 323 - 323
  • [4] COMBINATION CHEMOTHERAPY OF ARA-C-RESISTANT LEUKEMIA-P388 (P388 ARA-C) WITH INHIBITORS OF PURINE AND PYRIMIDINE BIOSYNTHESIS
    TRADER, MW
    SCHABEL, FM
    LASTER, WR
    BROCKMAN, RW
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1983, 24 (MAR): : 265 - 265
  • [5] COLLATERAL SENSITIVITY (CS) OF ARA-C-RESISTANT LEUKEMIA-P388 (P388/ARA-C) TO INHIBITORS OF PURINE BIOSYNTHESIS (IPUB) AND OR PYRIMIDINE BIOSYNTHESIS (IPYB)
    BROCKMAN, RW
    SCHABEL, FM
    LASTER, WR
    TRADER, MW
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1983, 24 (MAR): : 295 - 295
  • [6] EVALUATION OF NEW ANTHRACYCLINES ON P388-LEUKEMIA SENSITIVE (P388/S) OR RESISTANT (P388/R) TO DOXORUBICIN (DX)
    GERONI, CM
    PODESTA, A
    BARBIERI, BM
    GIULIANI, FC
    CASAZZA, AM
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1983, 24 (MAR): : 280 - 280
  • [7] THERAPY OF P388 LEUKEMIA WITH BENZALDEHYDE
    BALAZOVA, E
    KOZA, I
    NEOPLASMA, 1988, 35 (06) : 725 - 728
  • [8] BIOCHEMICAL AND MORPHOLOGICAL-STUDIES IN P388 SENSITIVE AND DOXORUBICIN RESISTANT (P388 DX) LEUKEMIA-CELLS
    FACCHINETTI, T
    MALISANO, G
    SALARDI, S
    GERONI, C
    BELLINI, O
    ESPOSITO, G
    GIULIANI, FC
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1985, 26 (MAR): : 343 - 343
  • [9] Effects of xanthine derivatives on the influx and efflux of doxorubicin in P388 and DOX-resistant P388 leukemia cells
    Sadzuka, Y
    Egawa, Y
    Sawanishi, H
    Miyamoto, K
    Sonobe, T
    TOXICOLOGY LETTERS, 2002, 135 (1-2) : 137 - 144
  • [10] INFLUENCE OF HOMOHARRINGTONINE ON ULTRASTRUCTURE OF MURINE LEUKEMIA P388 CELLS
    ZHOU, JX
    ZHOU, PQ
    DAI, ZQ
    XU, B
    ACTA PHARMACOLOGICA SINICA, 1985, 6 (02): : 140 - 144
12345